News

Opus Genetics

Clinical 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

Opus Genetics is advancing clinical programs for inherited retinal diseases, specifically targeting LCA5 and BEST1 mutations. The company recently announced FDA alignment on a Phase 3 trial design for OPGx-LCA5 and provided a timeline for OPGx-BEST1 results. These gene therapy programs aim to address the underlying genetic causes of rare vision loss.

We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.